(LYEL) Lyell Immunopharma - Overview
Stock: CAR T-Cell, IMPT-314, Epi-R, Stim-R, NR4A3
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 89.8% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.04 |
| Alpha | 65.32 |
| Character TTM | |
|---|---|
| Beta | 1.189 |
| Beta Downside | 1.469 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.90% |
| CAGR/Max DD | -0.30 |
Description: LYEL Lyell Immunopharma January 28, 2026
Lyell Immunopharma (NASDAQ: LYEL) is a clinical-stage biotechnology firm focused on next-generation chimeric antigen receptor (CAR-T) cell therapies. Its pipeline leverages engineered resistance to T-cell exhaustion (c-Jun overexpression, NR4A3 knockout), stem-like T-cell enrichment (Epi-R, CD62L-positive selection), and a synthetic-cell mimetic platform (Stim-R). The lead candidate, IMPT-314-a dual-targeting CD19/CD20 CAR-T-currently resides in a combined Phase 1/2 trial for relapsed/refractory large B-cell lymphoma, while a separate solid-tumor program remains in pre-clinical development. The company was founded in 2018 and operates out of South San Francisco.
Key recent metrics (as of the Q4 2025 Form 10-Q):
• Cash and cash equivalents ≈ $118 million, giving roughly 12 months of runway at current burn (~$10 M / month).
• Interim Phase 1/2 data for IMPT-314 reported a 71 % overall response rate (ORR) and a 45 % complete response rate in the first 18 evaluable patients, with no Grade ≥ 3 cytokine release syndrome-benchmarks that exceed historical CAR-T averages for this indication (≈ 60 % ORR).
• The broader CAR-T market is projected by Grand View Research to reach $15 billion by 2029, expanding at a ~20 % CAGR, driven by expanding indications and next-generation designs that address T-cell exhaustion.
Assumption: the disclosed interim data will hold in larger cohorts; any adverse safety signals or manufacturing setbacks could materially alter the valuation.
Given the nascent stage of Lyell’s solid-tumor assets and the competitive dynamics of the CAR-T space, a deeper dive into the company’s cash runway, manufacturing scalability, and upcoming data read-outs is warranted-ValueRay’s analyst tools can help surface those details efficiently.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -325.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA -15.35 > 1.0 |
| NWC/Revenue: 722.7k% < 20% (prev 661.2k%; Δ 61.6k% < -1%) |
| CFO/TA -0.40 > 3% & CFO -165.0m > Net Income -325.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.3m) vs 12m ago 42.55% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.01% > 50% (prev 0.01%; Δ -0.00% > 0%) |
| Interest Coverage Ratio: -1.69 > 6 (EBITDA TTM -190.4m / Interest Expense TTM 121.1m) |
Altman Z'' -15.00
| A: 0.73 (Total Current Assets 328.2m - Total Current Liabilities 31.9m) / Total Assets 408.0m |
| B: -3.62 (Retained Earnings -1.48b / Total Assets 408.0m) |
| C: -0.40 (EBIT TTM -204.6m / Avg Total Assets 513.6m) |
| D: -18.75 (Book Value of Equity -1.48b / Total Liabilities 78.8m) |
| Altman-Z'' Score: -29.42 = D |
What is the price of LYEL shares?
Over the past week, the price has changed by -8.32%, over one month by -6.54%, over three months by +28.45% and over the past year by +104.96%.
Is LYEL a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the LYEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.7 | 30.6% |
| Analysts Target Price | 29.7 | 30.6% |
| ValueRay Target Price | 20.2 | -11% |
LYEL Fundamental Data Overview February 05, 2026
P/B = 1.6576
Revenue TTM = 41.0k USD
EBIT TTM = -204.6m USD
EBITDA TTM = -190.4m USD
Long Term Debt = 44.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.97m USD (from shortTermDebt, last fiscal year)
Debt = 44.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -79.3m USD (from netDebt column, last quarter)
Enterprise Value = 272.1m USD (547.5m + Debt 44.3m - CCE 319.6m)
Interest Coverage Ratio = -1.69 (Ebit TTM -204.6m / Interest Expense TTM 121.1m)
EV/FCF = -1.64x (Enterprise Value 272.1m / FCF TTM -165.5m)
FCF Yield = -60.83% (FCF TTM -165.5m / Enterprise Value 272.1m)
FCF Margin = -403.7k% (FCF TTM -165.5m / Revenue TTM 41.0k)
Net Margin = -794.3k% (Net Income TTM -325.7m / Revenue TTM 41.0k)
Gross Margin = unknown ((Revenue TTM 41.0k - Cost of Revenue TTM 8.16m) / Revenue TTM)
Tobins Q-Ratio = 0.67 (Enterprise Value 272.1m / Total Assets 408.0m)
Interest Expense / Debt = 11.89% (Interest Expense 5.26m / Debt 44.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.6m (EBIT -204.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.30 (Total Current Assets 328.2m / Total Current Liabilities 31.9m)
Debt / Equity = 0.13 (Debt 44.3m / totalStockholderEquity, last quarter 329.1m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -79.3m / EBITDA -190.4m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -79.3m / FCF TTM -165.5m)
Total Stockholder Equity = 336.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.41% (Net Income -325.7m / Total Assets 408.0m)
RoE = -96.68% (Net Income TTM -325.7m / Total Stockholder Equity 336.8m)
RoCE = -53.68% (EBIT -204.6m / Capital Employed (Equity 336.8m + L.T.Debt 44.3m))
RoIC = -47.98% (negative operating profit) (NOPAT -161.6m / Invested Capital 336.8m)
WACC = 10.23% (E(547.5m)/V(591.7m) * Re(10.30%) + D(44.3m)/V(591.7m) * Rd(11.89%) * (1-Tc(0.21)))
Discount Rate = 10.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.15%
Fair Price DCF = unknown (Cash Flow -165.5m)
EPS Correlation: -55.95 | EPS CAGR: -27.14% | SUE: 0.53 | # QB: 0
Revenue Correlation: -63.90 | Revenue CAGR: -75.26% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.14 | Chg30d=+0.795 | Revisions Net=+2 | Analysts=2
EPS next Year (2026-12-31): EPS=-9.05 | Chg30d=+1.947 | Revisions Net=+4 | Growth EPS=+14.7% | Growth Revenue=-100.0%